Imbruvica Patient Assistance Program Transition Information

AbbVie is pleased to welcome you to our new Imbruvica Patient Assistance Program. As Johnson & Johnson Patient Assistance Foundation’s (“JJPAF”) program for Imbruvica is coming to a close, we extend our heartfelt greeting to you here at AbbVie.

Important dates to note

Our patient assistance program will step in where JJPAF leaves off, ensuring eligible patients continue to have access to Imbruvica. For more information, please visit our FAQs.

New forms availability

Now available

If you are still taking Imbruvica and are in need of assistance in 2024, you will need to apply directly to the new program administered by AbbVie. 

IMBRUVICA application (English)
IMBRUVICA application (Spanish)

refill deadline

December 29, 2023

If you are currently enrolled in the JJPAF Imbruvica® Patient Assistance program, you may continue getting your prescribed and approved refills through December 29th, 2023.

Enrollment begins

January 2, 2024

With JJPAF coverage for Imbruvica coming to a close, patients transitioning from JJPAF can begin enrolling with AbbVie on January 2nd, 2024. Applications will be available no later than December 15th, 2023. Please visit after December 15th, 2023 for more information on how to apply.

AbbVie's Patient Assistance

At AbbVie, we believe that people who need our medicines should be able to get them. That’s why AbbVie provides free AbbVie medicine to qualifying patients. Our Patient Assistance Programs are intended for people that live in the United States, have limited or no health insurance coverage and demonstrate qualifying financial need. 

This program supports patients who:

  • Are being treated by a licensed U.S. health care provider on an outpatient basis and prescribed an AbbVie medicine that is included in our assistance program
  • Have limited or no health insurance coverage
  • Demonstrate qualifying financial need
  • Live in the United States

For more information on the new program and latest updates please continue to visit or alternatively you may listen to a recording of the information by dialing: 1-833-268-5170.

Frequently asked questions